Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Stifel Upgrades Linde to Buy

Stifel Upgrades Linde to Buy

Stifel analyst Andreas Heine upgrades Linde (NYSE:LIN) from Hold to Buy.

byBenzinga Newsdesk

August 10, 2022

1 minute read

Stifel analyst Andreas Heine upgrades Linde (NYSE:LIN) from Hold to Buy.

Analyst Ratings

The Latest Analyst Ratings for aTyr Pharma

By Benzinga Insights

May 23, 4:01 PM

aTyr Pharma (NASDAQ:LIFE) has observed the following analyst ratings within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat…

LIFE

GameStop Q4 Earnings Smash Wall Street Expectations: Reports Profitability For First Time In Over Half A Decade

By Kevin Malone

March 27, 5:07 PM

In a stunning turn of events, GameStop Corporation (NYSE: GME) has defied all odds, marking its return to profitability for the first time in over six years.

Analyst Ratings

Evaluating Hasbro: Insights From 6 Financial Analysts

By Benzinga Insights

January 2, 9:00 AM

Hasbro (NASDAQ:HAS) underwent analysis by 6 analysts in the last quarter, revealing a spectrum of viewpoints from bullish…

HAS

Canaccord Genuity Maintains Hold on Edwards Lifesciences, Lowers Price Target to $91

By Benzinga Newsdesk

October 14, 7:53 AM

Canaccord Genuity analyst William Plovanic maintains Edwards Lifesciences (NYSE:EW) with a Hold and lowers the price target from $106 to $91.

Stifel Upgrades Linde to Buy

Related Posts

The Latest Analyst Ratings for aTyr Pharma

GameStop Q4 Earnings Smash Wall Street Expectations: Reports Profitability For First Time In Over Half A Decade

Evaluating Hasbro: Insights From 6 Financial Analysts

Canaccord Genuity Maintains Hold on Edwards Lifesciences, Lowers Price Target to $91